Rhythm Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Rhythm Pharmaceuticals, Inc.
After last month’s news of its proposed acquisition by AstraZeneca, Alexion Pharmaceuticals has bought a priority review voucher from Rhythm Pharmaceuticals, which would speed one of its development projects towards the marketplace.
A number of companies have sought to convince the European Medicine Agency that their drug merits a fast-track regulatory review.
Drug already approved for multiple rare genetic disorders of obesity shows significant weight-loss reduction in Bardet-Beidl syndrome, but not in the smaller indication of Alström syndrome.
Keeping Track: Orladeyo, Danyelza, Imcivree Bring CDER 2020 Novel Approval Count Even With Full-Year 2019
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
- Large Molecule
- Other Names / Subsidiaries
- Rhythm Metabolic, Inc.